A share price of Bicara Therapeutics Inc [BCAX] is currently trading at $12.91, up 9.78%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The BCAX shares have gain 7.85% over the last week, with a monthly amount drifted -29.34%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Bicara Therapeutics Inc [NASDAQ: BCAX] stock has seen the most recent analyst activity on December 06, 2024, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $42. Previously, Rodman & Renshaw started tracking the stock with Buy rating on November 05, 2024, and set its price target to $48. On October 08, 2024, TD Cowen initiated with a Buy rating. Stifel started tracking the stock assigning a Buy rating and suggested a price target of $47 on October 08, 2024. Morgan Stanley initiated its recommendation with a Overweight and recommended $35 as its price target on October 08, 2024.
Bicara Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $11.10 and $28.09. Currently, Wall Street analysts expect the stock to reach $35 within the next 12 months. Bicara Therapeutics Inc [NASDAQ: BCAX] shares were valued at $12.91 at the most recent close of the market. An investor can expect a potential return of 171.11% based on the average BCAX price forecast.
Analyzing the BCAX fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.11, Equity is -0.63 and Total Capital is -0.14. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 12.10 points at the first support level, and at 11.28 for the second support level. However, for the 1st resistance point, the stock is sitting at 13.41, and for the 2nd resistance point, it is at 13.90.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Bicara Therapeutics Inc [NASDAQ:BCAX] is 36.01. Also, the Quick Ratio is 36.01, while the Cash Ratio stands at 35.96.
Transactions by insiders
Recent insider trading involved RA CAPITAL MANAGEMENT, L.P., Director, that happened on Sep 16 ’24 when 1.83 million shares were purchased. Possible Members of 10% Group, Flynn James E completed a deal on Sep 17 ’24 to buy 70000.0 shares.
